Table 1 Clinical characteristics of the patients in the CERTIM multi-cancer cohort
N (%) | |
|---|---|
Sex | |
M | 38 (66%) |
F | 20 (44%) |
Age (year) | |
Median (range) | 66 (41–83) |
Tumor type | |
Non-small cell lung | 37 (64%) |
Small cell lung | 1 (2%) |
Melanoma | 5 (9%) |
Colon | 1 (2%) |
Renal | 10 (17%) |
Urothelial | 4 (7%) |
ECOG performance statusa | |
0 | 2 (3%) |
1 | 31 (54%) |
≥ 2 | 24 (42%) |
Previous lines of therapy | |
0 | 2 (3%) |
1 | 31 (53%) |
2 | 11 (19%) |
≥ 3 | 14 (24%) |
Anti-PD-1 | |
Nivolumab | 52 (90%) |
Pembrolizumab | 6 (10%) |
ORR | |
CR | 6 (10%) |
PR | 7 (12%) |
SD | 7 (10%) |
PD | 38 (65%) |